Drug Type Nanobody, TriTAC |
Synonyms- |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), FLT3 modulators(Tyrosine-protein kinase receptor FLT3 modulators), Protease modulators + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 02 Sep 2022 |